11:27 AM EDT, 04/10/2025 (MT Newswires) -- Clearmind Medicine ( CMND ) said Thursday that it has started a phase 1/2a clinical trial of CMND-100 in patients will alcohol use disorder at the Johns Hopkins University School of Medicine, the company's first clinical site in the US.

The biotechnology company said the trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 and will also include preliminary efficacy evaluations to assess its potential in reducing alcohol cravings and consumption.

Price: 0.95, Change: -0.03, Percent Change: -3.06